Page 455 - Essential Haematology

Index / 441

drug-induced immune heterophile antibodies 138 pathogenesis 246
thrombocytopenia 337 hexose monophosphate pathway prognosis 251
indications 372–3 22, 24 Reed–Sternberg cells 246
laboratory control 373–4 HFE gene, mutation 51–3 relapse 251
low molecular weight 373, 377 hirudin 374, 376 secondary cancers 251
pregnancy 416 histiocytes 121 staging 247, 249, 250
mode of action 371–2 disorders 122 treatment 250–2
osteoporosis 374 histiocytic cell neoplasms 270 white cell changes 382
pregnancy 416 WHO classifi cation 429 WHO classifi cation 429
standard 373 histiocytosis X 122 homocysteine 367, 368
thrombocytopenia induction HIV infection thrombophilia screening 370
373–4 anaemia 391 hookworm 41, 45
venous thrombosis 371–4 blood transfusion 403–4 hormone replacement therapy,
heparin-induced thrombocytopenia Burkitt lymphoma 268, 391 venous thrombosis risk

(HIT) 373–4 diffuse large B-cell lymphomas 369
hepatitis 267, 268, 391 Howell–Jolly body 30, 144
post-transfusion 408 EBV infection 391 human albumin solution 411
see also viral hepatitis glandular fever 135 human leukocyte antigens (HLA)
hepatitis B immunization, haematological changes 390–1, 129–30, 134, 135
thalassaemia major 98 392 allogeneic stem cell
hepatitis C, haemophilia A 348 haemophilia A 346, 348 transplantation 303–4,
hepatocellular disease 355 Hodgkin lymphoma 391 305
hepcidin 37, 38, 39 lymphoma febrile reactions from white cell
expression control 37 incidence 154 antibodies 407
gene mutations 53 treatment 391 inheritance pattern 305
iron overload 52 lymphopenia 139 matching 304
hephaestin 39 malignancy 391 molecular genetics 305
hereditary elliptocytosis 78, 79 non-Hodgkin lymphoma 391 molecular testing 304
molecular basis 78, 79 primary central nervous system nomenclature 304
hereditary haemochromatosis lymphoma 269 self molecules 135
51–3 Hodgkin lymphoma 151, 246–52 typing 304
hereditary haemorrhagic assessment of response to human plasma preparations
telangiectasia 331, 332 treatment 251 411–12
hereditary persistence of fetal biochemical fi ndings 247 human platelet antigens (HPA)
haemoglobin 93, 99 classifi cation 247, 248, 429 318
hereditary spherocytosis 24, 77–9 clinical features 246–7 human T cell lymphotropic virus 1
clinical features 78 combined modality therapy 250 (HTLV-1) 153, 243
haematological fi ndings 78 complications 251 blood transfusion 404
investigations 78 cutaneous 246 hydrogen peroxide 114–15
pathogenesis 78, 78 diagnosis 247, 248 hydrops fetalis
red cell aplasia 295 Epstein–Barr virus 246 haemolytic disease of the
treatment 79 haematological fi ndings 247 newborn 421, 422
herpes simplex virus (HSV) histological classifi cation 247, α-thalassaemia 92
allogeneic stem cell 248 hydroxycarbamide (hydroxyurea)
transplantation 310 history 246 CML 198
haematological malignancies HIV infection 391 essential thrombocythaemia 210
170, 171 late eff ects 251 polycythaemia vera 207
herpes zoster, CLL 236 nodular sclerosing type 248, 250 sickle cell anaemia 103–4